Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Raw Materials: 2022-2025

Historic Raw Materials for InMed Pharmaceuticals (INM) over the last 3 years, with Sep 2025 value amounting to $172,200.

  • InMed Pharmaceuticals' Raw Materials fell 37.26% to $172,200 in Q3 2025 from the same period last year, while for Sep 2025 it was $172,200, marking a year-over-year decrease of 37.26%. This contributed to the annual value of $258,300 for FY2025, which is 30.69% down from last year.
  • Per InMed Pharmaceuticals' latest filing, its Raw Materials stood at $172,200 for Q3 2025, which was down 33.33% from $258,300 recorded in Q2 2025.
  • In the past 5 years, InMed Pharmaceuticals' Raw Materials ranged from a high of $387,071 in Q1 2023 and a low of $172,200 during Q4 2024.
  • Over the past 3 years, InMed Pharmaceuticals' median Raw Materials value was $233,518 (recorded in 2023), while the average stood at $250,918.
  • Data for InMed Pharmaceuticals' Raw Materials shows a peak YoY increase of 78.55% (in 2024) and a maximum YoY decrease of 49.23% (in 2024) over the last 5 years.
  • Over the past 4 years, InMed Pharmaceuticals' Raw Materials (Quarterly) stood at $208,737 in 2022, then decreased by 28.66% to $208,737 in 2023, then soared by 31.48% to $172,200 in 2024, then crashed by 37.26% to $172,200 in 2025.
  • Its Raw Materials was $172,200 in Q3 2025, compared to $258,300 in Q2 2025 and $258,300 in Q1 2025.